Calimmune is committed to accelerating the promise of gene therapy to liberate patients from chronic and currently incurable diseases. To achieve this goal, Calimmune has built a suite of technologies to advance the delivery, manufacturing, and overall efficiency of these life-changing medicines. Calimmune’s lead development programs are novel ex vivo gene therapies for HIV and other hematologic diseases. 

Calimmune has been acquired by CSL Behring.